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Background: No nationwide studies on social position and prevalence of comorbidity among cancer survivors exist.
Methods: We performed a nationwide prevalence study defining persons diagnosed with cancer 1943–2010 and alive on the
census date 1 January 2011 as cancer survivors. Comorbidity was compared by social position with the non-cancer population.
Results: Cancer survivors composed 4% of the Danish population. Somatic comorbidity was more likely among survivors
(OR 1.59, 95% CI 1.57–1.60) and associated with higher age, male sex, short education, and living alone among survivors.
Conclusions: Among cancer survivors, comorbidity is common and highly associated with social position.
The number of cancer survivors is increasing in many countries
(Engholm et al, 2010; Maddams et al, 2012; de Moor et al, 2013),
mainly due to ageing populations and decreasing cancer mortality
as a result of better diagnostics and treatment (Moller et al, 2002;
Jemal et al, 2004; Australian Institute of Health and Welfare,
Cancer Australia & Australasian Association of Cancer Registries,
2008; Rowland and Bellizzi, 2008; Parry et al, 2011). To our
knowledge, no nationwide studies of social position and the
prevalence of comorbidity have been performed among cancer
survivors. Defining cancer survivors from date of diagnosis and
throughout their lives (National Cancer Institute, 2014), we
thoroughly characterised the national population of such survivors,
compared the total burden of severe somatic comorbidity in cancer
survivors and the non-cancer population, and described potential
differences by social position among the cancer survivors.
MATERIAL AND METHODS
Study design and population. We performed a cross-sectional
study of all people living in Denmark on 1 January 2011, who were
identified in the civil registration system, comprising 5 560 628
people (Pedersen, 2011). Since 1943, all cases of cancer have
been registered in the Danish Cancer Registry (Gjerstorff, 2011).
We identified all persons diagnosed with cancer (excluding benign
tumours, in situ cancers and non-melanoma skin cancers) in 1943–
2010 and classified them according to their first (index) cancer.
Somatic comorbidity measured by the Charlson Comorbidity
Index (CCI) was calculated based on discharge information
from 1978 (inpatient) and 1995 (outpatient) to census date from
the National Patient Registry (Lynge et al, 2011) and information
on all subsequent primary malignancies after the index cancer
from the Danish Cancer Registry (Charlson et al, 1987; Dalton
et al, 2008a). From the Danish Psychiatric Case Register (Mors
et al, 2011), we defined severe psychiatric comorbidity as hospital
contacts from 1969 (inpatient) or 1995 (outpatient) to the
census date for schizophrenia and psychosis and affective disorders
(Dalton et al, 2008a).
Education and cohabitation status was used as indicators for
social position. Information was derived from the Integrated
Database for Labour Market Research in Statistics Denmark
(Thygesen, 1995) and the Danish Civil Registration System
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containing information on all Danish residents. Social position
analyses were restricted to 30–90-year olds, as information on
education was not available for people born before 1920, and many
Danes finish their education in the late twenties. Highest attained
educational level was categorised as short (mandatory education,
7–9 years), medium, (high school or vocational education,
8–12 and 10–12 years of education for people born before and
after 1958, respectively), and long education (412 years, i.e.,
higher education). Cohabitation status was defined as cohabiting
(married or cohabiting with partner), widow/widower, divorced,
and single (not cohabiting and never married).
Statistical analysis. The prevalence of cancer survivors was
calculated from the number of people with a cancer diagnosis in
the population on 1 January 2011. To analyse the risk for a CCI
scoreX1 depending on being a cancer survivor, multivariate logistic
regression analyses were performed with adjustment for sex, age,
schizophrenia or psychosis, and affective disorders. The association
between education and cohabitation status and somatic comorbidity
was examined in 30–90-year olds by multivariate logistic regression
analyses stratified by cancer survivor or non-cancer population and
time since diagnosis and adjusted for education, cohabitation status,
sex, age, schizophrenia or psychosis, affective disorder, and cancer
diagnosis (only in cancer survivors). Age was modelled as a second-
order polynomial in all regression analyses.
RESULTS
On 1 January 2011, 227 704 cancer survivors were living
in Denmark, corresponding to 4% of the total population.
The median age of the cancer survivors was 67 years; 13% of
60–89-year olds and 18% of X90-year olds were cancer survivors
(Table 1). Nearly 8% of cancer survivors had had more than one
cancer (Table 2).
Median time since diagnosis was 6 years. Approximately one-
third of people with cancers of the lung, esophagus, stomach, and
pancreas had survived o1 year after diagnosis. One-third of
survivors of female genital cancers had received their diagnosis
X20 years before the census date, but only 4% of lung cancer
survivors (Supplementary Information S1).
A CCI score X1 was found for 40% of the cancer survivors
and for 16% of the non-cancer population, whereas prevalence
of affective disorders and schizophrenia or psychosis was similar
Table 1. Basic characteristics of 5 560628 people living in Denmark on 1 January 2011
Cancer survivors Non-cancer population
Total,
n¼227704
Men,
n¼94481
Women,
n¼133223
Total,
n¼5332924
Men,
n¼2662101
Women,
n¼2670823
Proportion cancer
survivorse
%a %a %a %a %a %a %
Age on 1 January 2011 (years)
0–29 2 3 1 37 38 37 o1
30–59 26 24 27 42 52 41 3
60–89 69 72 67 21 20 22 13
X90 3 2 4 1 o1 1 18
Charlson Comorbidity Index
0 60 56 63 85 84 85 3
1 19 20 18 11 11 10 7
X2 21 25 19 5 5 4 17
Schizophrenia or psychosis
Ever
diagnosed
1 1 1 1 1 1 4
Never
diagnosed
99 99 99 99 99 99 4
Affective disorder
Ever
diagnosed
4 3 5 3 2 3 6
Never
diagnosed
96 97 95 97 98 97 4
Totalb,
n¼218003
Menb,
n¼90789
Womenb,
n¼127214
Totalb,
n¼3313351
Menb,
n¼1637833
Womenb,
n¼1675518
%a %a %a %a %a %a %
Educationc
Short 26 24 28 16 15 17 10
Medium 49 51 47 52 55 50 6
Long 23 23 23 28 26 31 5
Cohabitation status
Cohabiting 65 75 58 71 74 69 6
Widow/
widower
18 9 24 7 3 11 15
Divorcee 11 8 12 9 8 11 7
Singled 7 8 6 13 15 10 3
aThe sum may exceed 100% due to rounding.
bRestricted to 30–90-year olds.
cExcluding unknown education: 2% of cancer survivors, 3% of non-cancer population.
dNot cohabiting and never married.
eThe proportion, who are cancer survivors of the total number of people in each category.
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(Table 1). The proportion of survivors with a CCI scoreX1 ranged
from 58% for lung cancer survivors to 29% for survivors of
malignant melanoma. In comparison with the non-cancer
population, the OR of all cancer survivors for having a CCI score
X1 was 1.59 (95% CI 1.57–1.60) after adjustment for sex and age.
Adjustments for psychiatric comorbidity did not change the
estimate. Male sex and older age were associated with significantly
increased odds for a CCI score X1 (data not shown).
Level of education and cohabitation status varied by cancer type,
but cancer survivors with short education had the highest
proportion of somatic and psychiatric comorbidity in all the age
groups (Supplementary Information S2). Compared with survivors
with higher education, those with short education had 57% higher
odds for having a CCI scoreX1 (95% CI 1.53–1.62), and survivors
with medium education had 33% higher odds (95% CI 1.29–1.36).
Living alone was also significantly associated with higher odds for a
CCI scoreX1 in comparison with cohabiting; divorced people had
the highest odds (OR 1.45, 95% CI 1.41–1.50) (Table 3). The social
gradient in somatic comorbidity was slightly smaller among cancer
survivors than the non-cancer population and tended to be smaller
with time after diagnosis (Table 3).
DISCUSSION
Cancer survivors have substantially higher odds for comorbid
diseases in addition to their cancer than the cancer-free population.
Short education and living alone were consistently associated with
higher odds for comorbid diseases.
Our results confirm the prevalence of cancer type, age, sex and
time since diagnosis found previously (Maddams et al, 2009; Siegel
et al, 2012; Underwood et al, 2012; de Moor et al, 2013; Gatta et al,
2013; Jarlbaek et al, 2014); however, this is the first study to report
results from a nationwide population with combined registry-based
information on both cancer, demography, comorbidity, and social
position.
Results from the National Health Interview Survey in the United
States (n¼ 7292) indicated a higher prevalence of somatic
comorbidity among both cancer survivors (57.7%) and matched
controls (45.2%) than in our study; however, the survey data on
comorbidity were self-reported in relation to functional limitations
(Yabroff et al, 2004). We ensured consistent reporting of severe
comorbid diseases leading to hospital contacts and found that
cancer survivors had significantly greater odds for somatic
comorbidity than the non-cancer population, which might be
due to preexisting morbidity, late effects of cancer and cancer
treatment, shared risk factors such as lifestyle, environmental
exposure, and genetics, or joint effects of these (Aziz, 2007).
Furthermore, the non-cancer illness of cancer survivors may not be
Table 2. Cancer-specific characteristics of 227704 cancer
survivors living in Denmark on 1 January 2011
Total,
n¼227704,
%a
Men,
n¼94481,
%a
Women
n¼133223,
%a
Index cancer typeb
Mouth, pharynx and larynx 2 4 1
Esophagus, stomach and
pancreas
1 2 1
Colon and rectum 11 13 10
Lung 3 3 3
Breast 23 o1 39
Female genitalia 10 - 17
Male genitalia 13 32 -
Kidney and bladder 8 14 4
Malignant melanoma 8 8 9
Central nervous system 6 6 6
Leukemias, NHL and HL 7 9 5
Other cancers 7 8 6
Age at diagnosis of index cancer (years)
0–29 6 8 6
30–59 46 35 51
60–89 48 56 42
X90 o1 o1 1
Time since diagnosis of index cancer (years)
o1 11 13 9
1–4 31 36 27
5–9 22 22 22
10–19 22 18 25
X20 15 11 18
No. of primary cancers after index cancerb
0 93 93 93
1 7 7 7
X2 1 1 1
Abbreviations: HL¼Hodgkin lymphoma; NHL¼ non-Hodgkin lymphoma.
aThe sum may exceed 100% due to rounding.
bExcluding benign tumours, cancer in situ, and non-melanoma skin cancers.
Table 3.Multivariate logistic regression analyses of the odds ratio (OR) with 95% confidence intervals (95% CIs) between somatic
comorbidity (CCIX1), education, and cohabitation status among cancer survivors (n¼218003) and the non-cancer population
(n¼3313351) aged 30–90 years, living in Denmark on 1 January 2011, adjusted for sex and age
Non-cancer
population,
n¼3313351
Cancer
survivors,
n¼218003
Cancer
survivors
o1 year
after
diagnosis,
n¼23958
Cancer
survivors
1–4 years
after
diagnosis,
n¼67262
Cancer
survivors
5–9 years
after
diagnosis,
n¼47577
Cancer
survivors
10–19 years
after
diagnosis,
n¼47539
Cancer
survivors
X20 years
after
diagnosis,
n¼31667
OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI OR 95% CI
Education
Short 1.71 1.70–1.73 1.57 1.53–1.62 1.74 1.60–1.89 1.64 1.56–1.72 1.63 1.53–1.72 1.49 1.41–1.58 1.40 1.31–1.51
Medium 1.34 1.33–1.35 1.33 1.29–1.36 1.39 1.29–1.49 1.35 1.29–1.40 1.34 1.27–1.41 1.31 1.25–1.38 1.24 1.17–1.32
Long 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Cohabitation status
Cohabiting 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference 1.00 Reference
Widow/widower 1.11 1.10–1.13 1.14 1.11–1.17 1.17 1.07–1.27 1.18 1.12–1.24 1.12 1.06–1.18 1.11 1.05–1.18 1.11 1.04–1.18
Divorced 1.48 1.47–1.50 1.45 1.41–1.50 1.52 1.40–1.66 1.46 1.38–1.54 1.49 1.40–1.59 1.43 1.35–1.53 1.33 1.24–1.44
Singlea 1.24 1.23–1.26 1.25 1.21–1.30 1.23 1.10–1.38 1.29 1.20–1.38 1.26 1.16–1.37 1.19 1.10–1.29 1.21 1.10–1.33
Abbreviation: CCI¼Charlson Comorbidity Index.
aNot cohabiting and never married.
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managed optimally (Earle and Neville, 2004) contributing to the
risk of hospitalisation for comorbidity.
Previous studies have shown that low social position is
associated with higher cancer incidence for selected cancers and
poorer survival after most cancers (Dalton et al, 2008b) and a
higher risk for comorbid disease at the time of cancer diagnosis
(Louwman et al, 2010). We show that the social gradient continues
into life after cancer, a gradient that could not be explained
by case-mix due to cancer type alone. We found that the social
differences were smaller among those who had survived longer,
which might be due to the social gradient in cancer survival
(Dalton et al, 2008b), and because comorbidity is a strong
predictor for early mortality from cancer (Yancik et al, 2001;
Piccirillo et al, 2004).
The primary aim of this study was to characterise comorbidity
and social position in a nationwide population of cancer survivors;
however, information on individual lifestyle and behaviour could
have provided further insight, as these are risk factors for both
cancer and comorbid diseases. As the aim was to investigate the
total burden of severe comorbidity, we included all comorbid
diseases occurring before and after the index cancer. As secondary
primary malignancies were included only for cancer survivors,
comorbidity might be a late effect of cancer treatment and/or due
to shared risk factors. Most comorbid conditions in people
with recent cancers date from before the index cancer, while
people with earlier cancers have comorbid conditions from after
the index cancer. Finally, time since diagnosis was truncated, as
cancer registration started in 1943; thus, people with cancers
diagnosed before 1943, and alive on 1 January 2011, were not
defined as cancer survivors but we expect the underestimation of
prevalence to be small.
This study, based on nationwide data, provides new insight into
the total burden of severe comorbidity in the growing group of
cancer survivors. Use of national registers prevents bias and
provides consistent, complete, and valid individual-level informa-
tion on social factors and morbidity, and the long tradition of
systematic registration of cancer in Denmark ensures almost
complete registration of cases.
CONCLUSION AND IMPLICATIONS
The population of Danish cancer survivors is large and some have
survived for decades after their initial diagnosis. Beyond being
impaired by the cancer treatment, cancer survivors are more
affected by other chronic disorders than their non-cancer fellows,
especially survivors with low social position. Further investigation
of the causes of social differences in comorbidity are important to
ensure equal access and optimal care and rehabilitation of both
cancer and comorbid diseases for all cancer survivors.
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